A Study of Oral LY317615 in Relapsed or Refractory Diffuse Large B-Cell Lymphomas.
Completed · Phase 2
Conditions studied: Non-Hodgkin's Lymphoma
In brief
This study will measure the effectiveness and any side effects of LY317615 in participants with diffuse large B-cell lymphoma (DLBCL: a sub-type of Non-Hodgkins Lymphoma).
Key facts
- Study ID
- NCT00042666
- Run by
- Eli Lilly and Company
- People needed
- 55
- Starts
- 2002-06-01
- Expected to finish
- 2008-09-01
- Last updated by the study team
- 2020-08-10
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- A diagnosis of recurrent or refractory DLBCL.
- Adequate organ functions.
- Able to swallow capsules.
You may not qualify if…
- More than 3 prior treatments for this disease.
- Serious heart problems.
Where it is running
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. — Royal Oak, Michigan, United States
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. — Minneapolis, Minnesota, United States
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. — Rochester, Minnesota, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.